A post hoc evaluation of the shift in spasticity category in individuals with multiple sclerosis-related spasticity treated with nabiximols.

Clara Grazia ChisariJoe GuadagnoPeyman AdjamianCarlos Vila SilvanTeresa GrecoMakarand BagulFrancesco Patti

Published in: Therapeutic advances in neurological disorders (2023)

A meaningful proportion of MSS patients treated with nabiximols shifted to a lower category of spasticity severity, typically maintained to the end of the 12-week study period.

Keyphrases

botulinum toxin
spinal cord injury
upper limb
multiple sclerosis
cerebral palsy
children with cerebral palsy
randomized controlled trial
white matter
placebo controlled